Adult Growth Hormone Deficiency

  • Dec 18, 2017 seekingalpha.com
    AEterna Zentaris: A Discussion Of The Cut-Off Point Issue – Seeking Alpha
    Read More
  • Dec 14, 2017 seekingalpha.com
    AEZS: The Unique Selling Points Of Macrilen – Seeking Alpha
    Read More
  • Dec 08, 2017 www.smarteranalyst.com
    Ahead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial Officer – Smarter Analyst
    Read More
  • Nov 27, 2017 globenewswire.com
    Aeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency – GlobeNewswire
    Read More
  • Jul 18, 2017 www.raredr.com
    Second FDA Review of Macrilen for AGHD Treatment Monitoring Underway – Rare Disease Report
    Read More
  • May 02, 2017 www.biopharmadive.com
    Late-stage failure puts an end to Aeterna Zentaris’ lead therapy – BioPharma Dive
    Read More
  • Apr 05, 2017 m.theinvestor.co.kr
    Global pharma firms eye Genexine’s new drug – The Investor
    Read More
  • Apr 02, 2017 www.medscape.com
    Longer-Acting Growth Hormones Promising for Adult GH Deficiency – Medscape
    Read More
  • Apr 02, 2017 www.businesswire.com
    Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017 – Business Wire
    Read More

Connect. Empower. Inspire.